| Name | Title | Contact Details |
|---|
CompassionWe embrace each persons’ journey, celebrating unique perspectives and situations free of judgment.TeamworkWe are one team. We celebrate each others’ successes and work together to overcome challenges.ExcellenceWe grow with each other, so we p...
Learn about who we are, our approach to scientific innovation, our areas of therapeutic focus, our products, commitments and more.
BenAstrum Pharma Broad is a Montrí©al, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Vision Innovation Partners unites the mid-Atlantic’s premier ophthalmology practices and surgery centers through good people, expert leadership, the sharing of best practices and the backing of a leading middle-market private equity firm.
Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to currently approved drugs. Each of Eupraxia`s product candidates has the potential to address therapeutic areas with high unmet medical need, and strives to provide improved patient benefit by delivering targeted, long-lasting activity with fewer side effects. In addition to Eupraxia`s lead product candidate, EP-104IAR, Eupraxia is developing a pipeline of earlier-stage long-acting formulations. Potential pipeline candidates include a range of drugs for indications such as post-surgical pain (EP-105), and post-surgical site infections (EP-201), each designed to improve on the activity and tolerability of approved drugs. Eupraxia is also developing a formulation of EP-104IAR for use in canine and equine osteoarthritis.